The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes

Abstract

Purpose. The pharmacology, pharmacokinetics, pharmacodynamics, clinical utility, adverse effects, dosage, and cost of lenalidomide are reviewed.

Summary. Lenalidomide is a thalidomide analogue approved for treatment of myelodysplastic syndromes (MDS) associated with a cytogenetic 5q deletion. In combination with dexamethasone, lenalidomide has been approved by the FDA in the United States for the treatment of relapsed or refractory multiple myeloma, and is sometimes used for induction therapy. Although the precise mechanism of action of lenalidomide remains unknown, it does exhibit antineoplastic and immunomodulatory properties. Lenalidomide is quickly absorbed after oral administration and is renally eliminated. In patients with myelodysplatic syndromes, lenalidomide reduces the need for transfusion. In patients with refractory or relapsed multiple myeloma, lenalidomide in combination with dexamethasone demonstrated a significantly longer time to tumor progression compared to placebo plus dexamethasone. Lenalidomide in combination with dexamethasone also elicited an objective response from patients with newly diagnosed symptomatic multiple myeloma. Treatment with lenalidomide was associated with neutropenia, thrombocytopenia, constipation, pruritus, and fatigue. Due to the teratogenic nature of thalidomide, lenalidomide must be obtained through a restrictive distribution program. The initial daily dosing of lenalidomide is 10 mg for MDS with a 5q deletion and 25 mg for relapsed or refractory multiple myeloma. Dose modifications are required for renal impairment and grade 3—4 adverse events.

Conclusion. Lenalidomide is an effective agent for the treatment of MDS with a 5q deletion and relapsed or refractory multiple myeloma.

Keywords

lenalidomide multiple myeloma myelodysplastic syndromes

Get full access to this article

View all access options for this article.

References

Coutre S. Myelodysplastic syndromes: disease overview and therapy options. Manag Care 2008; 17(7): 3-8.

Giagounidis A. , Fenaux P. , Mufti GJ , Muus P. , Platzbecker U. , Sanz G. et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008; 87(5): 345-52.

The NCCN Clinical Practice Guidelines in OncologyTM MYELODYSPLASTIC SYNDROMES (Version 1.2009) © 2009 National Comprehensive Cancer Network, Inc Available at: NCCN.org (accessed date June 8, 2009). To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.

Tuscano JM Multiple myeloma: epidemiology and therapeutic options. Manag Care 2008; 17(7): 9-15.

The NCCN Clinical Practice Guidelines in OncologyTM MULTIPLE MYELOMA (Version 1.2010). © 2009 National Comprehensive Cancer Network, Inc Available at: NCCN.org (accessed date June 8, 2009). To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.

Revlimid (lenalidomide). [Package insert] Summit, NJ; Celgene Corporation, 2009.

Raab MS , Podar K. , Breitkreutz I. , Richardson PG , Anderson KC Multiple myeloma. Lancet 2009; 374(9686): 324-39.

Jadersten M. , Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009; 265(3): 307-28.

Chen N. , Lau H. , Kong L. , Kumar G. , Zeldis JB , Knight R. et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47: 1466-75.

10.

List A. , Dewald G. , Bennett J. , Giagounidis A. , Raza A. , Feldman E. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355(14): 1456-65.

11.

Raza A. , Reeves JA , Feldman EJ , Dewald GW , Bennett JM , Deeg HJ et al. Phase II study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111(1): 86-93.

12.

Weber DM , Chen C. , Niesvizky R. , Prince HM , Harousseau JL , Dmoszynska A. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357(21): 2133-42.

13.

Dimopoulos M. , Spencer A. , Attal M. , Wang M. , Belch A. , Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357(21): 2123-32.

14.

Rajkumar SV , Hayman SR , Lacy MQ , Dispenzieri A. , Geyer SM , Kabat B. et al. Combination therapy with lenalidomide plus dexamethasone (Rev/ Dex) for newly diagnosed myeloma. Blood 2005 ; 106: 4050-3.

15.

Patel PH , Kondagunta GV , Schwartz L. , Ishill N. , Bacik J. , DeLuca J. et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 2008; 26: 273-6.

16.

Wiernik PH , Lossos IS , Tuscano JM , Justice G. , Vose JM , Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26(30): 4952-7.

17.

Treon SP , Soumerai JD , Branagan AR , Hunter ZR , Patterson CJ , Ioakimidis L. et al. Lenalidomide and rituximab in Waldenstrom macroglobulinemia. Clin Cancer Res 2009; 15: 355-60.

18.

Mansfield JC , Parkes M. , Hawthorne AB , Forbes A. , Probert CS , Perowne RC et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Aliment Pharmacol Ther 2007; 26(3): 421-30.

19.

Klasco RK ed. DRUGDEX® System [electronic version]. Greenwood Village, CO: Thomson Micromedex, Available at: http://www.thomsonhc.com (accessed date June 30, 2009).